Every Form 4 that Sanara MedTech Inc. (SMTI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SMTI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SMTI filings page.
Salamone Ann Beal reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. director Ann Beal Salamone received a grant of 4,154 shares of restricted common stock as compensation under the company’s 2024 Omnibus Long-Term Incentive Plan. Following this award, she directly holds 26,858 shares of Sanara MedTech common stock.
The restricted stock will vest on the earlier of the company’s 2027 annual shareholder meeting or June 4, 2027, as long as she continues providing certain services to Sanara MedTech through that date.
Ortwein Sara N reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. director Sara N. Ortwein received a grant of 4,616 shares of common stock as restricted stock under the company’s 2024 Omnibus Long-Term Incentive Plan. These shares were awarded at no cash cost and increase her direct holdings to 25,415 shares.
The restricted stock will vest on the earlier of the company’s 2027 annual shareholder meeting or June 4, 2027, as long as she continues providing specified services to Sanara MedTech through that date. This filing reflects a compensation-related equity award rather than an open-market share purchase or sale.
Mack Roszell III reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. director Mack Roszell III received a grant of 5,308 shares of restricted common stock as equity compensation. The award was made at no cash price and increases his direct holdings to 21,842 shares.
The restricted stock will vest on the earlier of the company’s 2027 annual shareholder meeting or June 4, 2027, as long as he continues providing certain services to Sanara MedTech Inc. through that date. The grant was issued under the company’s 2024 Omnibus Long-Term Incentive Plan.
TANZBERGER ERIC D reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. director Eric D. Tanzberger received a grant of 5,308 shares of common stock as restricted stock compensation, at a price of $0.00 per share. After this award, he directly holds 22,966 shares of Sanara MedTech common stock.
The restricted stock was granted under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan and will vest on the earlier of the 2027 annual shareholder meeting or June 4, 2027, provided he continues to provide certain services to the company through that date.
Nixon Ronald T reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. director and 10% owner Ronald T. Nixon received a grant of 4,154 shares of restricted common stock as equity compensation. The award was issued under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan at no cash cost to him.
The restricted stock will vest on the earlier of the company’s 2027 annual shareholder meeting or June 4, 2027, if he continues providing certain services to the company through that date. Following this grant, he holds 68,196 shares of common stock directly.
In addition, separate from his direct holdings, 963,856 shares are owned of record by CGI Cellerate RX, LLC and 2,452,731 shares are owned of record by FA Sanara, LLC. These entities may share voting and dispositive control with Mr. Nixon and related entities, who disclaim beneficial ownership of those shares except to the extent of their pecuniary interests.
DeSutter Robert Andrew reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. director Robert Andrew DeSutter reported receiving a grant of 5,539 shares of common stock as restricted stock, with no cash price per share. This is a compensation-related award, not an open-market purchase.
According to the filing, the restricted stock was granted under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan and will vest on the earlier of the 2027 annual shareholder meeting or June 4, 2027, as long as DeSutter continues providing specified services to the company. After this grant, he directly holds 28,740 shares of Sanara MedTech common stock.
Major Eric D reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. reported that director Eric D. Major received a grant of 4,846 shares of common stock as restricted stock under the company’s 2024 Omnibus Long-Term Incentive Plan. The grant was made at no cash cost to him and increases his direct holdings to 14,232 shares.
The restricted stock will vest on the earlier of the company’s 2027 annual shareholder meeting or June 4, 2027, as long as Major continues providing certain services to Sanara MedTech through that date. Until vesting, the award functions as equity-based compensation tied to his ongoing service to the company.
Myers Keith G reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. director Keith G. Myers reported receiving a grant of 4,385 shares of common stock as restricted stock under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The award was made at no cash cost per share and increases his directly held position to 9,325 shares.
The restricted stock will vest on the earlier of the company’s 2027 annual shareholder meeting or June 4, 2027, provided Myers continues to provide certain services to the company through that date.
Sanara MedTech Inc. Chief Executive Officer Yon Seth D reported an automatic share withholding related to equity compensation. On the vesting of 13,466 shares of restricted stock, 3,852 shares of common stock were withheld by the company to satisfy tax withholding obligations, based on a value of $21.06 per share. No shares were issued or sold in this transaction, and following the withholding, the CEO directly holds 109,546 shares of common stock.
Mackey Ashley M reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. reported that Controller Ashley M. Mackey received a grant of 2,804 shares of restricted common stock at no cash cost under the company’s 2024 Omnibus Long-Term Incentive Plan. The restricted stock vests in three equal installments on March 22 of 2027, 2028 and 2029, if she remains employed on each date.
The amended Form 4 corrects her post‑grant holdings to 4,967 common shares, revising an earlier filing that had overstated the amount as 5,067 shares.
Sanara MedTech Inc. reported a routine equity compensation event for Chief Operating Officer Jacob A. Waldrop. As 1,551 shares of previously granted restricted stock vested, 378 shares of common stock were withheld by the company to satisfy tax withholding obligations. The filing states that no shares were issued or sold in this transaction. Following the tax withholding disposition, Waldrop directly holds 24,377 shares of Sanara MedTech Inc. common stock.
Mackey Ashley M reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. reported that Controller Ashley M. Mackey received a grant of 2,804 shares of common stock as equity compensation. The shares were awarded at no cash cost and increased her direct holdings to 5,067 shares after the transaction.
According to the filing, the 2,804 granted shares are restricted stock issued under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. They will vest in three equal installments on March 22, 2027, March 22, 2028 and March 22, 2029, provided she remains employed with the company through each vesting date.
Waldrop Jacob A. reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. reported that Chief Operating Officer Jacob A. Waldrop received a grant of 13,956 shares of common stock as restricted stock under the company’s 2024 Omnibus Long-Term Incentive Plan. Following this equity award, his direct holdings total 24,755 shares of common stock.
The restricted stock will vest in three equal installments, with one-third of the shares vesting on March 22 of 2027, 2028 and 2029, provided he remains employed by Sanara MedTech through each vesting date. This is a compensation-related award rather than an open-market purchase or sale.
Taylor Elizabeth B reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. granted its Chief Financial Officer, Elizabeth B. Taylor, 12,687 shares of restricted common stock as equity compensation. These shares were awarded at no cash cost and increase her direct holdings to 17,632 common shares following the transaction.
The restricted stock will vest in three equal installments, with one-third vesting on March 22 of 2027, 2028, and 2029, respectively. Vesting is conditioned on her continued employment with Sanara MedTech through each vesting date, aligning a portion of her compensation with the company’s long-term performance.
Yon Seth D reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. reported that Chief Executive Officer Yon Seth D received a grant of 25,430 shares of common stock as restricted stock under the company’s 2024 Omnibus Long-Term Incentive Plan. Following this award, he directly holds 113,398 common shares.
The restricted stock will vest in three equal installments, with one-third of the shares vesting on March 22, 2027, 2028 and 2029, provided he remains employed by the company through each vesting date. This represents compensation rather than an open-market share purchase.
Sanara MedTech Inc. reported a routine equity compensation event for its Chief Executive Officer, Yon Seth D. On the vesting of 2,082 shares of previously granted restricted stock, the company withheld 596 shares of common stock to cover tax obligations, using a per-share value of $18.87. The footnote clarifies that no shares were issued or sold on the market in this transaction. Following the tax-withholding disposition, the CEO directly owns 87,968 shares of Sanara MedTech common stock.
Sanara MedTech Inc. Chief Executive Officer Seth D. Yon filed an amended insider report updating a prior tax-related share withholding. The company withheld 414 shares of common stock at $20.44 per share to cover taxes on the vesting of 1,446 restricted shares, correcting an earlier filing that had shown 491 shares withheld. This was a tax-withholding disposition only, and the filing states that no shares were issued or sold in the transaction. After this adjustment, Yon directly holds 88,564 shares of Sanara MedTech common stock.
Sanara MedTech Inc.’s Chief Executive Officer, Yon Seth D, reported a Form 4 showing a tax-withholding disposition of 491 shares of common stock on March 1, 2026. These shares were withheld by the company to cover tax obligations from the annual vesting of 1,446 previously granted restricted shares, at a reference price of $20.44 per share. The filing notes that no shares were issued or sold in this transaction, and the CEO’s directly held stake after the withholding was 88,487 common shares.
Sanara MedTech Inc. director and Chief Executive Officer Yon Seth D reported a tax-related share withholding tied to restricted stock vesting. The company withheld 873 shares of common stock to cover tax obligations when 3,049 previously granted restricted shares vested, and no shares were issued or sold in the market. After this withholding, Yon Seth D directly owns 88,978 shares of Sanara MedTech common stock.
Sanara MedTech Inc.’s Chief Operating Officer Jacob A. Waldrop reported an automatic share withholding related to equity compensation. On the transaction date, 714 shares of common stock were withheld by the company at $19.90 per share to cover tax obligations from the annual vesting of 2,930 restricted stock shares previously granted to him. The filing states that no shares were issued or sold in the open market as part of this tax-withholding disposition, and Waldrop’s direct holdings after the transaction total 10,799 common shares.
Sanara MedTech Inc. Chief Financial Officer Elizabeth B. Taylor reported a tax-related share disposition tied to vesting of restricted stock. On the vesting of 1,794 restricted shares, the company withheld 437 shares of common stock at $19.90 per share to cover tax withholding obligations.
The footnote clarifies that no shares were issued or sold on the open market; the shares were retained by the company to satisfy taxes. After this withholding transaction, Taylor directly owns 4,945 shares of Sanara MedTech common stock.
Sanara MedTech Inc. Controller Ashley M. Mackey reported a tax-related share disposition. The company withheld 149 shares of common stock at $19.90 per share to cover tax obligations tied to the vesting of 502 restricted shares. After this withholding, Mackey directly owns 2,263 common shares.